Virtual Alanine Scan of the Main Protease Active Site in Severe Acute Respiratory Syndrome Coronavirus 2

• Published in: International journal of molecular sciences Vol. 22; no. 18; p. 9837
• Main Authors: Nakayoshi, Tomoki, Kato, Koichi, Kurimoto, Eiji, Oda, Akifumi
• Format: Journal Article
• Language: English
• Published: Basel MDPI AG 11.09.2021; MDPI
• Subjects: Alanine; Chemical compounds; Coronaviruses; COVID-19; Drug resistance; main protease; Molecular dynamics; molecular dynamics simulation; Mutants; Mutation; Pharmacology; Protease; Protein structure; Proteinase; Proteins; Residues; Respiratory diseases; Severe acute respiratory syndrome coronavirus 2; Therapeutic targets; virtual alanine scan
• ISSN: 1422-0067; 1661-6596; 1422-0067
• DOI: 10.3390/ijms22189837

Recently, inhibitors of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) main protease (Mpro) have been proposed as potential therapeutic agents for COVID-19. Studying effects of amino acid mutations in the conformation of drug targets is necessary for anticipating drug resistance. In this study, with the structure of the SARS-CoV-2 Mpro complexed with a non-covalent inhibitor, we performed molecular dynamics (MD) simulations to determine the conformation of the complex when single amino acid residue in the active site is mutated. As a model of amino acid mutation, we constructed mutant proteins with one residue in the active site mutated to alanine. This method is called virtual alanine scan. The results of the MD simulations showed that the conformation and configuration of the ligand was changed for mutants H163A and E166A, although the structure of the whole protein and of the catalytic dyad did not change significantly, suggesting that mutations in His163 and Glu166 may be linked to drug resistance.